A $750 Billion Moonshot: Inside the Bond-Funded Push to Cure Disease

CHICAGO, IL – October 20, 2026 — The numbers surrounding America's healthcare crisis are as familiar as they are staggering. Alzheimer's, diabetes, heart disease, and cancer collectively drain the United States economy of more than $1.1 trillion annually in direct medical costs. For decades, the federal response has been a slow, methodical drip of research grants and incremental policy shifts. Now, a newly reinvigorated advocacy group is proposing a financial and structural shock to the system: a $750 billion, bond-funded initiative that places corporate executives side-by-side with scientists to eradicate the nation's deadliest illnesses.

The American Center for Cures, an initiative operating under the 501(c)(3) umbrella of The Giving Back Fund, launched a nationwide campaign today urging voters to make disease eradication the singular bipartisan issue of the November 3 midterm elections. Co-founders Lou Weisbach and Dr. Richard Boxer are calling on the electorate to demand that every candidate for the House, Senate, and White House commit to passing legislation that would establish and fully fund their ambitious blueprint.

"Disease is the only issue that affects every single American," Weisbach said in the organization's announcement. "When cancer or Alzheimer's strikes your family, the price of gas and the cost of groceries suddenly stop mattering. Nothing else matters."

But behind the emotional appeal lies a highly complex, fiercely debated financial mechanism. As investors and policymakers scrutinize the proposal, the question is not whether curing disease is a worthy goal, but whether financing a $750 billion medical moonshot through U.S. Treasury bonds is a stroke of macroeconomic genius or a fiscal house of cards.

The Economics of a $750 Billion Gamble

The most forensic examination of the American Center for Cures' proposal must begin with its funding model. Rather than relying on standard congressional appropriations—the lifeblood of existing federal research—the initiative proposes issuing $750 billion in U.S. Treasury bonds over a six-year period.

Under this framework, the federal government's only immediate fiscal responsibility would be the escalating annual interest payments. These payments would start at $6 billion in the first year, rise to $12 billion in the second, and cap at $36 billion by the sixth year. The organization claims this interest would be entirely offset by pharmaceutical licensing fees generated from the new, non-curative compounds discovered during the research process. The principal bond debt, meanwhile, would be repaid through the massive federal healthcare savings generated by Medicare and Medicaid as diseases are prevented or cured.

"What a great way to bring down the deficit," Weisbach noted.

However, public finance experts and healthcare economists note that this "pay-for-success" model, while theoretically appealing, is fraught with unprecedented risk at this scale. Budgeting based on projected healthcare savings is notoriously difficult. The Congressional Budget Office typically views such long-term, speculative savings with extreme caution. If the promised cures take decades rather than years, or if the pharmaceutical licensing fees fall short of the billions required to cover the bond interest, taxpayers would be left holding the bag on a massive expansion of the national debt.

Furthermore, banking on licensing fees assumes a consistently high volume of marketable, non-curative drug discoveries that private pharmaceutical companies are willing to license at premium rates. While social impact bonds exist in the public sector, they are typically deployed on a micro-level, targeting specific community outcomes. Scaling this mechanism to rival the defense budget represents uncharted territory for federal fiscal policy.

Business Executives vs. Federal Bureaucracy

Beyond the financing, the American Center for Cures is proposing a radical restructuring of how biomedical research is managed. Once funded, the initiative would launch 16 separate, private-sector efforts. Fourteen of these units would be dedicated to a single disease, each armed with a $36 billion budget. Two additional units would receive $108 billion each: one focused on artificial intelligence and another on orphan and other diseases. A remaining $30 billion would serve as a strategic reserve fund.

The defining characteristic of these 16 units is their leadership structure. Each would be guided not just by leading scientists and physicians, but by "proven business leaders" operating with clear goals and strict accountability for results.

This corporate-style approach is a direct challenge to the traditional peer-review grant system employed by the National Institutes of Health (NIH), which currently distributes over $40 billion annually. It also presents an interesting parallel to the recently established Advanced Research Projects Agency for Health (ARPA-H). Modeled after DARPA, ARPA-H was designed to fund high-risk, high-reward research with a sense of urgency.

Policy analysts point out that while the American Center for Cures shares ARPA-H's desire for rapid, use-driven innovation, its insistence on placing private-sector executives at the helm creates a potential jurisdictional minefield. Establishing 16 new, heavily funded entities could trigger an intense competition for scientific talent, potentially cannibalizing researchers from NIH-funded academic institutions. The challenge will be proving that a business-led model can accelerate discoveries without sacrificing the rigorous, methodical peer review that ensures patient safety and scientific integrity.

The Men Behind the Mission

Understanding the audacity of this proposal requires a close look at its architects. The American Center for Cures is driven by a unique partnership between a seasoned entrepreneur and a highly credentialed medical insider.

Lou Weisbach built his reputation as the founder of Ha-Lo Industries, growing it into the world's largest promotional products company with an international footprint. While Ha-Lo eventually filed for bankruptcy protection in 2002 following a series of aggressive acquisitions, Weisbach's career has been defined by his ability to scale operations rapidly and leverage high-level political connections. His background brings a distinct "growth-at-all-costs" corporate mentality to the typically measured world of medical research.

Balancing Weisbach's corporate background is Dr. Richard Boxer, a clinical professor of urology at UCLA and a heavyweight in health policy. A three-time cancer survivor himself, Dr. Boxer brings undeniable scientific credibility to the initiative. He served as a Presidential Appointee to the National Cancer Advisory Board under two different administrations and has acted as a health policy advisor to the White House. His involvement signals to the medical establishment that this is not merely a corporate vanity project, but a serious scientific endeavor.

Their organization operates as a fiscally sponsored project of The Giving Back Fund, a reputable 501(c)(3) public charity known for managing philanthropic vehicles for high-net-worth individuals and celebrities. This structure provides the American Center for Cures with immediate administrative infrastructure and non-profit credibility as it solicits public support.

A Single-Issue Midterm Gamble

The timing of this announcement is highly strategic. By launching the #TheCuresPledge campaign just weeks before the November 3 midterms, the organization is attempting to cut through a deeply polarized political landscape. They are asking voters to record videos explaining why curing disease matters to them, and to flood the inboxes of their representatives and local candidates.

History, however, shows that pushing this specific agenda is an uphill battle. A previous iteration of this proposal, the American Center for Cures Act of 2005, was introduced in the U.S. Senate but ultimately failed to gain the necessary traction. Legislative watchers note that while "curing disease" is a universally popular concept, securing bipartisan consensus for a $750 billion off-budget expenditure is a monumental task.

Yet, the political calculus in 2026 may be shifting. The economic toll of chronic disease is no longer a distant projection; it is a present reality crippling Medicare and Medicaid budgets. By framing the initiative not as an expense, but as a deficit-reduction strategy through future savings, Weisbach and Boxer are directly targeting the fiscal anxieties of both sides of the aisle. Whether candidates will formally commit to a $750 billion bond issuance in the final days of a heated election cycle remains to be seen, but the American Center for Cures has ensured that the cost of inaction is now front and center on the political stage.